Clinical Oncology - Issue 2/2016
Review
100
Anticancer Effect of Fish Oil – a Fable or the Truth?
J. Neuwirthová, B. Gál, P. Smilek, P. Urbánková, R. Kostřica
107
News in Adjuvant Therapy of Non-seminomatous Germ Cell Testicular Tumors of Stage I
T. Pokrivčák, R. Lakomý, R. Vyzula
Comment
111
Original Articles
113
Change in Quality of Life Measured over Time in Czech Women with Breast Cancer
L. Anderkova, N. Elfmarkova, T. Sverak, H. Peterkova, D. Brancikova, M. Bendová, M. Protivánková, K. Benesova, L. Dusek, J. Jarkovský, L. Minar, K. Skrivanova
122
Discordance between Clinical and Pathological TNM Classifications in Patients with Oropharyngeal Cancer – Influence on Treatment and Prognosis
P. Kordač, D. Kalfeřt, K. Smatanová, J. Laco, M. Vošmik, P. Čelakovský, V. Chrobok
127
Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy
I. Richter, J. Dvořák, V. Hejzlarová, J. Chalupa, M. Sochor, I. Stankuš, L. Barsová, M. Holikova, J. Forster, J. Bartoš
Case Report
133
The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma – a Case Study
J. Kopecký, O. Kubeček
139
Papillary Carcinoma of Thyroid Gland in a Two-year-old Child
B. Uhliarová, A. Hajtman
Clinical Oncology
2016 Issue 2
Most read in this issue
- Extravasation of Cytostatic Drugs – Prevention and Best Practices
- Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy
- Anticancer Effect of Fish Oil – a Fable or the Truth?
- The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma – a Case Study